Dr. Jim Wilson Departs UPenn to Launch New Gene Therapy Companies Dr. Jim Wilson has departed the University of Pennsylvania after 31 years, where he led the Gene Therapy Program, [….]
Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases, including the first ever gene edited therapeutic. The CMC package required to effectively [….]
Join QIAGEN for a BioInsights-hosted webinar on June 11 to hear from Ryan Massopust, a Scientist at Asklepios BioPharmaceutical, Inc. (AskBio), about his use of quadruplex digital PCR (dPCR) to [….]
Secretary of the Maryland Department of Commerce Kevin Anderson invites you to Meet Maryland’s cell and gene therapy leaders at a welcome reception at the University of Maryland BioPark. Network with [….]
The Festival of Genomics and Biodata is returning to Boston! Join us on Wednesday, June 12th – Thursday, June 13th, 2024, at the Boston Convention & Exhibition Center for inspirational [….]
Jill Faulkner Joins Vector BioMed as Associate Sales Director, Business Development
Regenxbio and UPenn Lose Legal Battle Over Muscular Dystrophy Treatment Patent to Sarepta Published on January 6, 2024 In a major legal showdown over patents and innovation, Sarepta Therapeutics (SRPT.O) [….]
Join us to mix, mingle & celebrate Philly’s contributions to the industry as we cheers to the region’s continued growth.
SwanBio Makes its Case for Rare Neurological Disease Gene Therapy By Mark TerryMay 16, 2023 SwanBio Therapeutics, based in Philadelphia, issued a healthcare resource use study that confirmed the burden [….]
Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Vector BioMed
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…
